| |
Radiopharmaceutical
Therapy
Radiopharmaceutical Therapy is the treatment
of cancer with radioactive pharmaceuticals. Zevalin is a
monoclonal antibody with a radioactive isotope (Yttrium-90)
attached. As part of the Zevalin treatment regiment this
is the first radioimmunotherapy medication approved by the
FDA to treat a non-Hodgkin's
lymphoma patient. When injected into a patient with B-cell
non-Hodgkin's
lymphoma, Zevalin circulates through the body until it locates
and binds with a protein found on the surface of specific
cells. It then delivers radiation to specific and neighboring
cells to damage the targeted malignant cells. Zevalin therapeutic
regimen is delivered on an outpatient basis traditionally
over eight days. The treatment regimen includes various other
procedures in conjunction with a medical oncologist and diagnostic
imaging lab.
|
|
|
|
